Page 225 - 2021_02-Haematologica-web

sCADM1 as a new diagnostic marker of ATLL
nificantly lower than before treatment (Figure 4B). A signif- icant reduction in serum LDH, PVL, and WBC after chemotherapy was also observed in acute-type ATLL patients (Figure 4C-E). Plasma sCADM1 levels were exam- ined in three patients with acute-type ATLL who received
allo-HSCT (Online Supplementary Table S3). Although all three patients exhibited elevated levels of serum sIL2Rα, 2 of the 3 patients showed normal (case 3) or slightly high levels (case 1) of plasma sCADM1. Notably, in one patient (case 2) with elevated levels of both sIL2R and sCADM1,
Figure 5. Plasma sCADM1 is useful for monitoring disease progression in adult T-cell leukemia/lymphoma patients. Plasma soluble form of cell adhesion molecule 1 (sCADM1) concentrations along with various prognostic parameters including serum interleukin-2 receptor α (sIL2Rα ), lactate dehydrogenase (LDH), and white blood count (WBC) count were monitored in six patients with adult T-cell leukemia/lymphoma (ATLL) before and after acute crisis (day 0). The drug regimen is indi- cated at the top of the figure: VP-16, etoposide; LSG15, VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, and prednisone [VCAP], doxorubicin, ranimus- tine, and prednisone [AMP], and vindesine, etoposide, carboplatin, and prednisone [VECP]); PSL: prednisolone; KW-0761: mogamulizumab; THP-COP: pirarubicin, cyclophosphamide, vincristine, and prednisolone.
haematologica | 2021; 106(2)
539